Van Andel Institute

KYCO: Know Your Company

Reveal Profile

4 November 2025

1) Overview of the Company

Van Andel Institute (VAI) is an independent 501(c)(3) nonprofit biomedical research and science education organization founded by Jay and Betty Van Andel in 1996 and headquartered in Grand Rapids, Michigan. The Institute operates with more than 500 scientists, educators, and staff focused on improving human health through biomedical research and science education to enhance human life and future generations. VAI’s research concentrates primarily on cancer epigenetics and Parkinson’s disease, while also investigating osteoarthritis, neurofibromatosis type 1, Alzheimer’s disease, prion diseases, Ewing sarcoma, and other conditions.

David Van Andel, son of founders Jay and Betty Van Andel, has served as Chairman and Chief Executive Officer since the Institute’s establishment in 1996. The organization operates through three distinct entities: Van Andel Institute (VAI), Van Andel Research Institute (VARI), and Van Andel Education Institute (VAEI), with VAI serving as the parent organization that performs functions for and carries out the purposes of both VARI and VAEI.

VAI’s 400,000 square foot facility, designed by architect Rafael Viñoly and constructed in two phases (completed in 2000 and 2009), is located on Grand Rapids’ Medical Mile and achieved LEED Platinum certification for its Phase II expansion. The Institute’s research is organized into five departments: Epigenetics, Neurodegenerative Science, Metabolism and Nutritional Programming, Cell Biology, and Structural Biology, supported by comprehensive Core Technologies and Services including bioinformatics, genomics, cryo-electron microscopy, and pathology services.

In 2024, VAI published 122 peer-reviewed papers, with 63 appearing in high-impact journals, and has facilitated 15 VAI-SU2C Epigenetics Dream Team clinical trials and 10 clinical trials co-funded with Cure Parkinson’s. The Institute has established significant collaborations including the Van Andel Institute-Stand Up To Cancer Epigenetics Dream Team led by Chief Scientific Officer Peter A. Jones and partnerships with The Cure Parkinson’s Trust through the Linked Clinical Trials initiative. VAI Graduate School offers an accredited Ph.D. program in cellular and molecular biology, while VAI Education provides K-12 science education programs, professional development for teachers, and inquiry-based learning resources.

2) History

Van Andel Institute was founded in 1996 by Jay and Betty Van Andel with a vision to build an independent institute that would embrace novel approaches to biomedical research and science education, developing a network of collaborations from West Michigan to every corner of the world. The founding reflected Jay and Betty Van Andel’s generosity and deep care for humankind, with their son David Van Andel appointed as Chairman and CEO at the Institute’s establishment, a position he has maintained since 1996.

The Institute’s early leadership appointments shaped its trajectory, with Dr. Gordon Van Wylen appointed as the first Director of Van Andel Education Institute and Dr. Luis Tomatis named the first President of Van Andel Institute in 1996. In 1997, Van Andel Education Institute hosted its first Van Andel Educators Institute, a national symposium for school principals and superintendents, establishing the organization’s commitment to educational outreach. The groundbreaking ceremony for VAI’s facilities in downtown Grand Rapids occurred in 1998, followed by the appointment of respected cancer scientist Dr. George Vande Woude as Research Director of Van Andel Research Institute in 1999.

Research operations began in 1999 in temporary laboratory space at Butterworth Hospital, while VAI played a pivotal role in establishing Grand Rapids’ Medical Mile, a health sciences and medical corridor serving as a source for innovative biomedical research, cutting-edge clinical care, and economic growth in West Michigan. Phase I of VAI’s construction was completed in 2000, with the facility hosting its first scientific symposium and establishing a scientific seminar series, later renamed in memory of Dr. Han-Mo Koo, a VARI scientist who died of cancer in 2004.

The Institute experienced a significant loss in 2004 with the passing of founders Jay and Betty Van Andel. The following year marked institutional expansion with the founding of Van Andel Institute Graduate School, which received a charter from the State of Michigan to confer Master’s and Ph.D. degrees, and the unveiling of “Life,” a glass sculpture commissioned by Jay Van Andel in memory of Betty Van Andel, created by world-renowned glass artist Dale Chihuly. Van Andel Institute Graduate School welcomed its first students in 2007, the same year construction began on Phase II building expansion, which was completed in 2009.

International collaboration expanded in 2007 with the establishment of the VARI/SIMM Center for Drug Discovery in Shanghai, China, through a partnership between VARI and the Shanghai Institute of Materia Medica. Leadership transitions occurred in 2009 when Jeffrey Trent was appointed VARI president and research director, succeeding Dr. George Vande Woude who stepped down to focus on research. In 2013, Dr. Peter Jones was appointed Van Andel Research Institute’s Chief Scientific Officer after 37 years at the University of Southern California, with VARI committing to becoming a global epigenetics research hub.

The Institute faced significant legal challenges related to federal grant disclosure requirements. In December 2019, Van Andel Research Institute agreed to pay $5.5 million to resolve allegations that it violated the False Claims Act by failing to disclose Chinese government grants that funded two VARI researchers between January 2012 and August 2019. A second settlement occurred in September 2021, when VARI agreed to pay $1.1 million for allegedly failing to disclose a foreign component involving a National Institutes of Health funding award, related to allegations involving undeclared biological research samples and undisclosed affiliations with China’s programs.

Recent developments include the October 2024 announcement that Dr. Jonathan D. Licht will serve as the next president and chief scientific officer of Van Andel Institute, continuing the Institute’s evolution as a leading biomedical research organization. Over its 28-year history, Van Andel Institute has grown from a vision of two philanthropists into a globally recognized research and education institution with more than 500 scientists, educators, and staff dedicated to improving human health through cutting-edge biomedical research and science education.

3) Key Executives

David Van Andel has served as Chairman and Chief Executive Officer of Van Andel Institute since the organization’s establishment in 1996. The son of founders Jay and Betty Van Andel, David Van Andel is a graduate of Hope College in Holland, Michigan, and has extensive experience as an entrepreneur in the natural and life science products industry. He currently serves on Amway’s Board of Directors, where he is a member of the Executive, Governance and Audit committees, and has played a prominent role in bringing professional hockey back to Grand Rapids as co-owner and chairman of the Grand Rapids Griffins.

Peter A. Jones, Ph.D., D.Sc. hon serves as President and Chief Scientific Officer of Van Andel Institute. Dr. Jones is internationally recognized as a pioneer in epigenetics, particularly for his seminal 1980 discovery that DNA methylation impacts gene expression and cellular differentiation. He joined VAI in 2013 after 37 years at the University of Southern California, where he most recently directed USC’s Norris Comprehensive Cancer Center from 1993 to 2011. Dr. Jones is past president of the American Association for Cancer Research and is an elected fellow of the National Academy of Sciences, the American Academy of Arts and Sciences, the American Association for the Advancement of Science, and the American Association for Cancer Research Academy.

Timothy Myers, MBA, CPA serves as Vice President, Chief Administrative Officer and Chief Financial Officer. Myers has been with Van Andel Institute in various financial leadership capacities and oversees the Institute’s administrative and financial operations. According to 2023 tax filings, Myers received total compensation of $571,257, reflecting his senior executive role in managing VAI’s financial affairs.

Eric C. Swindell, Ph.D. serves as Dean and Chief Academic Officer of Van Andel Institute Graduate School. Dr. Swindell provides academic leadership for VAI’s Ph.D. program in cellular and molecular biology and oversees the Graduate School’s educational mission. He works closely with faculty to ensure the program maintains its research-intensive, interdisciplinary approach that prepares students for careers as independent investigators.

Thomas R. Curran, Jr., J.D. serves as General Counsel for Van Andel Institute. Curran provides legal oversight and counsel to the organization across its research, education, and operational activities. According to 2023 tax filings, Curran received total compensation of $623,122, indicating his senior role in the Institute’s leadership structure.

Terra Tarango serves as Director and Education Officer of Van Andel Institute for Education. Tarango was appointed to this role in 2016, bringing over 20 years of experience in educational publishing and services. She previously served as president of Staff Development for Educators, a professional development company in New Hampshire, and has designed print and digital curriculum for kindergarten through 12th-grade students at Houghton Mifflin Harcourt.

Eric Sturdy was appointed as Vice President of Philanthropy in June 2025, bringing more than 25 years of strategic fundraising leadership across community-based nonprofits, healthcare and higher education. Sturdy’s appointment reflects VAI’s commitment to advancing its philanthropic initiatives and strengthening relationships with donors who support the Institute’s research and educational missions.

Craig Reynolds joined Van Andel Institute as Vice President of Research Compliance in October 2022 following a national search. Reynolds came to VAI from the University of Michigan, where he most recently served as Assistant Vice President for Research-Sponsored Projects. He has extensive experience in research and grants administration, having held positions at the University of Pennsylvania, Central Michigan University and the National Science Foundation, and has earned several awards from the National Council of University Research Administrators.

Ted Heilman was named as Van Andel Institute’s chief investment officer, effective January 2, 2026. Heilman joined VAI in 2007 and most recently served as associate director and senior portfolio manager. In his new role, Heilman will be responsible for managing the Institute’s endowment, succeeding Kathleen Vogelsang, who is retiring after two decades of exceptional leadership.

Linda Zarzecki, MBA serves as Vice President for Human Resources and Title IX Coordinator for Van Andel Institute Graduate School. Zarzecki oversees the Institute’s human resources functions and ensures compliance with educational and employment regulations. Her role encompasses employee relations, benefits administration, and maintaining VAI’s commitment to creating an inclusive workplace environment.

4) Ownership

Van Andel Institute operates through a distinctive ownership structure established by its founders Jay and Betty Van Andel in 1996. The organization consists of three related entities: Van Andel Institute (VAI), Van Andel Research Institute (VARI), and Van Andel Education Institute (VAEI), with VAI serving as the parent organization that performs functions for and carries out the purposes of both VARI and VAEI. This structure reflects the founders’ vision to build an independent institute that would embrace novel approaches to biomedical research and science education.

David Van Andel, son of founders Jay and Betty Van Andel, has maintained his position as Chairman and Chief Executive Officer since the Institute’s establishment in 1996, providing continuity of founding family leadership across the organization’s 28-year history. The Van Andel family’s continued involvement reflects their deep commitment to the Institute’s mission and their role as the primary stewards of the organization’s strategic direction.

The Institute operates as a 501(c)(3) nonprofit organization, with its governance structure reflecting the founder’s philanthropic intentions. According to consolidated financial statements, Van Andel Institute and its affiliates maintain significant financial resources, with total assets of $2.02 billion and net assets of $2.01 billion as of November 2023. The organization’s substantial endowment enables it to operate with considerable independence, supporting its research and educational activities without reliance on government funding.

Van Andel Institute’s board structure includes separate boards for each entity: the Van Andel Institute Board of Trustees chaired by David Van Andel includes business leaders John Kennedy (President & CEO of Autocam Medical), Mark Meijer (President of Life E.M.S. Ambulance), and Connie Chang (Chief Operating Officer of ONL Therapeutics), with Kyle Van Andel serving as Board Observer and Associate Director of the David and Carol Van Andel Family Foundation. The Van Andel Research Institute Board of Trustees includes distinguished medical and scientific leaders such as Dr. Ralph DeBerardinis from University of Texas Southwestern, Dr. James B. Fahner from Helen DeVos Children’s Hospital, and Dr. Max Wicha from University of Michigan Rogel Cancer Center.

The Institute’s ownership model reflects the Van Andel family’s long-term commitment to biomedical research and education, with David Van Andel and his wife Carol actively engaged through the David and Carol Van Andel Family Foundation, which serves as executive director. This family foundation structure demonstrates the continuing philanthropic engagement of the founding family beyond the Institute’s initial establishment, ensuring sustained support for its research and educational missions.

5) Financial Position

Van Andel Institute maintains an exceptionally strong financial position with total assets of $2.02 billion and net assets of $2.01 billion as of November 2023, reflecting the organization’s substantial endowment and financial stability. The Institute’s financial strength is built upon a $2.3 billion endowment that has grown significantly under the leadership of Chief Investment Officer Kathleen Vogelsang, who has managed the portfolio since the Institute’s founding and will retire at the end of 2025.

The organization’s revenue structure demonstrates both the benefits and volatility associated with endowment-dependent operations. In 2024, VAI’s revenue was $112.7 million, representing a significant decrease from $340 million in 2023. However, the 2023 figure was unusually high due to a $220 million transfer from the endowment specifically used to pay off long-term debt on the Institute’s building, demonstrating prudent debt management and the flexibility provided by substantial endowment resources.

Van Andel Institute operates with considerable financial independence, enabling it to pursue high-risk, high-reward research projects without heavy reliance on external funding constraints. The Institute received $25 million in NIH funds in 2024, representing a relatively small portion of its overall financial resources compared to its endowment-supported operations. This financial structure provides operational stability while allowing VAI to focus on cutting-edge research areas that might not receive traditional government funding.

The Institute’s financial management has earned recognition from external evaluators, with Charity Navigator awarding VAI a Four-Star rating and 94% overall score for accountability and financial management. This rating reflects strong financial stewardship, transparency in operations, and effective use of resources to support the organization’s mission. The high rating demonstrates investor and donor confidence in VAI’s financial management practices and governance structure.

VAI’s endowment strategy has focused on long-term growth and sustainability, enabling the organization to weather market volatility while supporting ongoing research and educational operations. The substantial financial resources allow the Institute to attract top scientific talent through competitive compensation packages, maintain state-of-the-art research facilities and equipment, and pursue ambitious research collaborations without being constrained by traditional funding cycles.

The organization’s financial position also enables strategic investments in infrastructure and technology, including the $10 million investment in the David Van Andel Advanced Cryo-Electron Microscopy Suite and ongoing facility improvements that maintain VAI’s position as a world-class research institution. The financial strength provides flexibility to respond to emerging scientific opportunities and to support both established researchers and promising early-career scientists.

Van Andel Institute’s debt management strategy reflects conservative financial planning, as evidenced by the decision to use endowment resources to eliminate long-term facility debt in 2023. This approach reduces ongoing financial obligations and provides greater operational flexibility while maintaining the endowment’s long-term growth potential for future research support.

6) Market Position

Van Andel Institute has established itself as a prominent player in the competitive biomedical research landscape, ranking fifth among nonprofit research organizations in biological sciences in the United States according to the Nature Index, and seventeenth globally. This ranking represents a remarkable achievement for an institution of VAI’s size and relative youth, demonstrating its ability to compete with much larger and more established research organizations. The Institute’s focus on cancer epigenetics and Parkinson’s disease has positioned it as a leader in specialized research areas that represent significant unmet medical needs.

The Institute’s research productivity places it among elite biomedical research organizations globally. In 2024, VAI published 122 peer-reviewed papers, with 63 appearing in high-impact journals, reflecting both the quantity and quality of its scientific output. Multiple VAI scientists have been named to the prestigious Clarivate Highly Cited Researchers list, with Dr. Russell Jones and Dr. Peter W. Laird recognized as leaders whose research ranks in the top 1% by citations in their respective fields. This recognition demonstrates VAI’s ability to conduct research that significantly influences scientific understanding and clinical practice.

VAI’s collaborative research model has created competitive advantages in translating laboratory discoveries into clinical applications. The Van Andel Institute–Stand Up To Cancer Epigenetics Dream Team, co-led by Chief Scientific Officer Dr. Peter Jones, has launched 15 clinical trials to date, representing a successful bridge between basic research and patient care. Similarly, the Institute’s partnership with The Cure Parkinson’s Trust through the International Linked Clinical Trials initiative has supported 10 clinical trials, demonstrating VAI’s ability to leverage collaborative relationships to accelerate research translation.

The Institute’s strategic location in Grand Rapids, Michigan, provides both advantages and challenges in the competitive research environment. While Grand Rapids offers cost advantages compared to major metropolitan areas like Boston, San Francisco, or New York, VAI must compete with more established research hubs for top scientific talent. However, the Institute’s location at the heart of Grand Rapids’ Medical Mile has enabled it to play a catalytic role in developing a regional biomedical research cluster, creating synergies with nearby academic institutions and healthcare systems.

VAI’s financial independence through its substantial endowment provides significant competitive advantages in the research marketplace. Unlike many academic institutions that rely heavily on federal funding, VAI can pursue high-risk research projects and maintain research programs during funding cycles that might challenge other organizations. This financial flexibility enables the Institute to compete effectively for top scientific talent and to invest in cutting-edge research infrastructure that supports breakthrough discoveries.

The Institute’s educational programs contribute to its competitive position by training the next generation of biomedical researchers. The VAI Graduate School’s Ph.D. program maintains exceptional outcomes with an average time to degree completion of 5.3 years and 96% of alumni employed in science/research or pursuing higher education. This track record enhances VAI’s reputation and helps attract high-quality graduate students who contribute to the Institute’s research productivity.

VAI’s market position in specific therapeutic areas reflects its strategic focus on underserved research domains. In cancer epigenetics, the Institute leverages Dr. Jones’s pioneering research to maintain leadership in a rapidly growing field with significant therapeutic potential. In Parkinson’s disease research, VAI’s collaborative approach through international partnerships positions it as a key player in drug repurposing and clinical translation efforts.

The Institute faces competitive challenges from larger academic medical centers and pharmaceutical companies with greater resources and broader research portfolios. However, VAI’s focused approach, collaborative model, and financial independence enable it to compete effectively in specialized research areas while maintaining the agility to respond quickly to emerging scientific opportunities.

7) Legal Claims and Actions

Van Andel Institute has faced significant federal enforcement actions resulting in two major settlements totaling $6.6 million between December 2019 and September 2021, both related to violations of grant disclosure requirements involving Chinese government funding and research collaborations.

In December 2019, Van Andel Research Institute agreed to pay $5.5 million to resolve allegations that it violated the False Claims Act by failing to disclose Chinese government grants that funded two VARI researchers between January 2012 and August 2019. The Department of Justice alleged that VARI submitted federal grant applications and progress reports to the National Institutes of Health without disclosing “Other Support” from Chinese sources, including funding from China’s Thousand Talents Program received by a researcher identified as “Professor 1.” The government contended that VARI was aware of these Chinese affiliations, including receiving a letter stating that Professor 1 was receiving “generous support” from the Chinese Thousand Talents Program, yet failed to take adequate steps to investigate the researchers’ foreign funding sources.

The 2019 settlement specifically addressed VARI’s handling of a June 2018 incident where the Institute learned about Chinese grants while reviewing a press release for a researcher’s publication but removed references to those grants rather than disclosing them to NIH. Despite receiving an August 2018 letter from NIH Director Francis Collins reminding institutions to disclose “support coming from foreign governments or other foreign entities” and a November 2018 email citing specific concerns about potential nondisclosures, VARI retained an outside consulting firm and sent a December 2018 letter to NIH asserting that disclosure was not required because “there was no undisclosed overlap of any budgetary resources, commitment, or scientific endeavor” between the Chinese and NIH grants. The government alleged that VARI acted with “deliberate ignorance or reckless disregard for the truth” in making this representation.

A second enforcement action occurred in September 2021, when VARI agreed to pay an additional $1.1 million to resolve allegations involving undisclosed foreign ties to NIH grants. This investigation was prompted by U.S. Customs and Border Protection stopping a former VARI researcher at Detroit Metro Airport in January 2020 with undeclared biological research samples in his luggage, who told CBP the samples were intended for a VARI professor’s laboratory. The settlement addressed allegations that VARI failed to disclose a foreign component of a National Institutes of Health award and failed to disclose foreign research support for two VARI researchers who served as principal investigators on NIH awards.

In addition to the financial settlements, NIH imposed Specific Award Conditions on all of VARI’s NIH grants, requiring personal executive-level certifications to the accuracy of NIH submissions, withdrawing certain expanded grant authorities, and removing all VARI grants from the Streamlined Non-Competing Award Process (SNAP). These conditions remained in place through September 30, 2022, or until NIH assessed and accepted VARI’s completed Corrective Action Plan and summary report.

Both settlements involved allegations that VARI did not adequately investigate researchers’ foreign affiliations despite being aware of Chinese connections, and that the Institute failed to properly disclose “Other Support” as required by NIH policies. The government emphasized that obtaining research funding from NIH is a highly competitive process, and nondisclosures and false statements to granting agencies are especially harmful because they distort competition, disadvantage applicants who play by the rules, and undermine agencies’ decision-making on the use of their limited resources.

The enforcement actions reflected the government’s broader initiative to address undisclosed foreign influence in U.S.-based research, with U.S. Attorney Andrew Birge stating that “False Claims Act penalties are harsh by design” and expressing hope that “the word gets out on the importance of full disclosure with the government.” The cases established VARI as the first organization to face financial penalties in the government’s crackdown on inappropriate or nondisclosed foreign involvement in U.S. research, with previous cases having pursued only individual investigators.

8) Recent Media

In October 2024, Van Andel Institute announced a significant leadership transition, appointing Dr. Jonathan D. Licht as its next president and chief scientific officer, effective early 2025. Dr. Licht, who previously led the University of Florida Health Cancer Institute to achieve National Cancer Institute designation in 2023, will succeed Dr. Peter A. Jones, who has led VAI since 2013. Dr. Jones will remain at the Institute to continue his research. Further executive changes include the announced retirement of Chief Investment Officer Kathleen Vogelsang at the end of 2025 after two decades, during which the endowment grew to $2.3 billion; she will be succeeded by Ted Heilman, who joined VAI in 2007. The Institute also hired Eric L. Sturdy as Vice President of Philanthropy in June 2025 and appointed Dr. Eric Swindell as the new dean and chief academic officer of the VAI Graduate School, effective December 2023.

VAI received several multimillion-dollar research grants between 2023 and 2025. In September 2023, Chief Scientific Officer Dr. Peter A. Jones was granted a seven-year, nearly $7.9 million Outstanding Investigator Award from the National Cancer Institute, a renewal of a previous $7.8 million award, to support his cancer epigenetics research. VAI scientist J. Andrew Pospisilik, Ph.D., in collaboration with a researcher from Maine Medical Center Research Institute, secured a five-year, $9.6 million Transformative Research Award from the National Institutes of Health. A February 2025 report noted that a proposed policy change by the NIH to cap indirect costs on federal grants could pose a financial risk to research institutions, citing that VAI received $25 million in NIH funds in 2024. Media in 2025 also reported that VAI’s revenue for 2024 was $112.7 million, a significant decrease from $340 million in 2023; a spokesperson clarified the 2023 figure was unusually high due to a $220 million transfer from its endowment to pay off long-term debt on its building.

The Institute has continued its focus on Parkinson’s disease research through its partnership with the U.K. charity Cure Parkinson’s. In March 2023, the organizations renewed their co-funding agreement for the International Linked Clinical Trials initiative, pledging a combined USD $4.5 million in match-funding for another three years. This collaborative program, which focuses on repurposing existing drugs, has been instrumental in advancing clinical trials, including a Phase 3 trial of the cough medicine ingredient ambroxol, which began in early 2023, and a Phase 2 trial of the anti-inflammatory drug dapansutrile, announced in February 2024. Since its inception in 2012, the iLCT program has supported numerous trials, with 21 ongoing as of March 2023.

Media in June 2024 revisited Van Andel Research Institute’s prior legal settlements with the U.S. government as part of broader coverage on federal scrutiny of foreign research support at U.S. institutions. A Science magazine article highlighted that the Institute’s settlements in 2019 and 2021, which totaled $6.6 million, were for failing to properly disclose foreign research ties. The report noted that the second settlement with VAI resulted in a requirement for a senior executive to personally sign off on all NIH submissions relating to “other support.”

9) Strengths

World-Class Scientific Leadership and Research Excellence

Van Andel Institute has assembled an internationally recognized team of scientists and researchers who represent the pinnacle of biomedical research expertise. The Institute’s Chief Scientific Officer, Dr. Peter A. Jones, is a globally recognized pioneer in epigenetics whose seminal 1980 discovery that DNA methylation impacts gene expression helped launch the entire field of epigenetics. Dr. Jones is an elected fellow of the National Academy of Sciences, the American Academy of Arts and Sciences, the American Association for the Advancement of Science, and the American Association for Cancer Research Academy. The Institute’s faculty includes multiple scientists named to the prestigious Clarivate Highly Cited Researchers list, with Dr. Russell Jones and Dr. Peter W. Laird recognized as leaders in their fields whose research ranks in the top 1% by citations. This exceptional scientific leadership is further demonstrated by Dr. Jones’s election to the National Academy of Medicine in 2024, considered one of the highest honors in medicine and health.

Leading Research Infrastructure and Advanced Technologies

Van Andel Institute operates from a state-of-the-art 400,000 square foot facility designed by renowned architect Rafael Viñoly, with Phase II achieving LEED Platinum certification. The Institute houses world-class research infrastructure including the David Van Andel Advanced Cryo-Electron Microscopy Suite, featuring a $10 million investment in cutting-edge microscopes including an FEI Titan Krios cryo-electron microscope. VAI’s comprehensive Core Technologies and Services offer advanced capabilities in bioinformatics, genomics, cryo-electron microscopy, flow cytometry, optical imaging, pathology, and transgenic services, providing researchers with access to technologies that support breakthrough discoveries. The Institute also maintains a College of American Pathologists-accredited Biorepository containing more than one million formalin-fixed paraffin-embedded blocks, representing a valuable resource for translational research.

Strong Financial Foundation and Endowment Management

Van Andel Institute operates with exceptional financial stability, maintaining total assets of $2.02 billion and net assets of $2.01 billion as of November 2023. The Institute’s substantial endowment, which has grown to $2.3 billion under the leadership of Chief Investment Officer Kathleen Vogelsang, provides significant independence and long-term sustainability for research operations. This financial strength enables VAI to pursue high-risk, high-reward research projects and attract top scientific talent without relying heavily on external funding constraints. The Institute’s commitment to financial stewardship is reflected in its 94% rating from Charity Navigator, earning it a Four-Star rating for accountability and financial management.

Innovative Collaborative Research Programs

Van Andel Institute has established itself as a leader in collaborative biomedical research through strategic partnerships that accelerate discovery and clinical translation. The Van Andel Institute–Stand Up To Cancer Epigenetics Dream Team, co-led by Dr. Peter Jones, represents a groundbreaking multi-institutional collaboration that has launched 15 clinical trials to date, translating promising epigenetic treatments into patient care. The Institute’s partnership with The Cure Parkinson’s Trust through the International Linked Clinical Trials initiative has supported 10 clinical trials, representing innovative approaches to repurposing existing drugs for Parkinson’s disease treatment. These collaborations demonstrate VAI’s ability to bridge the gap between laboratory discoveries and clinical applications while leveraging expertise from leading institutions worldwide.

High-Impact Research Productivity and Recognition

Van Andel Institute consistently demonstrates exceptional research productivity and scientific impact. In 2024, VAI published 122 peer-reviewed papers, with 63 appearing in high-impact journals, reflecting the quality and significance of its research output. The Institute ranks fifth among nonprofit research organizations in biological sciences in the United States according to the Nature Index, and seventeenth globally, a remarkable achievement for an institution of its size and age. VAI’s research has led to significant discoveries including the development of new blood tests for pancreatic cancer, identification of epigenetic targets for cancer treatment, and insights into the metabolic factors that influence immune cell function and cancer therapy effectiveness.

Comprehensive Educational Mission and Training Programs

Van Andel Institute operates a multifaceted educational enterprise that spans from K-12 science education through doctoral training. The VAI Graduate School offers an accredited Ph.D. program in cellular and molecular biology with exceptional outcomes, including an average time to degree completion of 5.3 years and 96% of alumni employed in science/research or pursuing higher education. The Institute’s K-12 education programs serve thousands of students annually through summer camps, field experiences, and classroom resources, while providing professional development for teachers nationwide. VAI’s educational impact extends globally through inquiry-based learning approaches that foster curiosity, creativity, and critical thinking in the next generation of scientists and problem solvers.

Strategic Geographic Location and Community Impact

Van Andel Institute is strategically positioned in Grand Rapids, Michigan, at the heart of the city’s Medical Mile, contributing significantly to the region’s transformation into a biomedical research hub. The Institute’s presence has catalyzed economic development and attracted additional medical and research institutions to the area, creating a synergistic environment for biomedical innovation. Grand Rapids offers cost advantages compared to major metropolitan areas while providing access to skilled talent from regional universities and medical centers. The Institute’s location also facilitates collaboration with nearby academic institutions and healthcare systems, enhancing its research capabilities and clinical translation opportunities.

Exceptional Governance and Leadership Continuity

Van Andel Institute benefits from stable, visionary leadership under Chairman and CEO David Van Andel, who has led the organization since its founding in 1996, providing continuity of mission and strategic direction. The Institute’s governance structure includes distinguished boards of trustees with expertise spanning business, medicine, and scientific research, ensuring oversight that supports both scientific excellence and operational effectiveness. The organization’s commitment to transparency and accountability is demonstrated through comprehensive financial reporting and adherence to best practices in nonprofit governance, contributing to stakeholder confidence and long-term sustainability.

10) Potential Risk Areas for Further Diligence

Regulatory Compliance and Grant Disclosure Risk

Van Andel Institute faces significant ongoing risks related to federal grant compliance following two substantial settlements totaling $6.6 million with the Department of Justice between December 2019 and September 2021. The Institute’s history of failing to adequately disclose foreign funding sources and components represents a pattern that could indicate systemic compliance vulnerabilities. NIH imposed Specific Award Conditions on all VARI grants requiring personal executive-level certifications for submission accuracy, withdrawal of expanded grant authorities, and removal from streamlined processes through September 2022. The government’s allegation that VARI acted with “deliberate ignorance or reckless disregard for the truth” in representations to NIH suggests potential ongoing oversight challenges in managing complex international research collaborations and disclosure requirements.

Leadership Transition and Key Person Risk

Van Andel Institute faces substantial leadership transition risk with multiple senior executive changes occurring in 2025-2026. Dr. Peter A. Jones, who led the Institute as Chief Scientific Officer since 2013, will be succeeded by Dr. Jonathan D. Licht in early 2025, representing a significant shift in scientific leadership direction. Additionally, Chief Investment Officer Kathleen Vogelsang will retire at the end of 2025 after building the Institute’s $2.3 billion endowment from inception, with succession to Ted Heilman who joined in 2007. The concentration of institutional knowledge and relationships in these long-serving executives creates potential disruption risks during transition periods, particularly given Jones’s role in establishing VAI as a leader in cancer epigenetics and Vogelsang’s responsibility for the Institute’s substantial financial resources.

International Collaboration and Reputational Risk

The Institute’s history of enforcement actions specifically related to Chinese research collaborations may limit its ability to participate in international partnerships and could affect researcher recruitment from global talent pools. VAI previously operated the VARI-SIMM Center for Drug Discovery in Shanghai through a partnership with Shanghai Institute of Materia Medica, but the enforcement actions suggest potential ongoing challenges in managing such international relationships while maintaining compliance with evolving federal disclosure requirements. The Institute’s reputation in the scientific community may face ongoing scrutiny, particularly given the government’s characterization of institutional failures to investigate researchers’ foreign affiliations despite having knowledge of Chinese connections.

Financial Concentration and Endowment Management Risk

Van Andel Institute operates with exceptional financial concentration, maintaining total assets of $2.02 billion with net assets of $2.01 billion as of November 2023, representing significant dependence on endowment performance for operational sustainability. The organization’s revenue volatility is evidenced by the substantial decrease from $340 million in 2023 to $112.7 million in 2024, with the 2023 figure including an unusually high $220 million transfer from endowment to pay off building debt. This financial structure creates vulnerability to market volatility and requires sophisticated investment management capabilities during the upcoming leadership transition in the investment office.

Cybersecurity and Data Protection Vulnerabilities

Van Andel Institute experienced a data breach in 2020 when donor information including names, email addresses, and phone numbers was accessed through a ransomware attack against third-party vendor Blackbaud. As a biomedical research organization handling sensitive research data, patient information through its biorepository operations, and maintaining extensive collaborations with external partners, VAI faces ongoing cybersecurity risks that could impact research operations, donor relationships, and regulatory compliance. The Institute’s role in managing the College of American Pathologists-accredited Biorepository containing more than one million specimens creates additional data protection obligations and potential liability exposure.

Research Integrity and Publication Risk

The Institute’s research productivity of 122 peer-reviewed papers in 2024, with 63 appearing in high-impact journals, creates ongoing risks related to research integrity, reproducibility, and potential publication challenges. Given the Institute’s previous compliance issues with federal grants, there may be heightened scrutiny of research methodologies, data management practices, and publication standards. The organization’s ranking as fifth among nonprofit research organizations in biological sciences creates pressure to maintain research quality and output levels that could strain resources or create incentives for questionable research practices.

Generic Industry Considerations

Emerging biomedical research organizations face standard challenges including intense competition for federal funding, increasing regulatory complexity around research conduct and disclosure requirements, and the need to maintain cutting-edge technological capabilities amid rapidly evolving scientific methodologies. The broader research sector continues to experience pressure from changing federal priorities, potential budget constraints, and evolving international collaboration restrictions that could impact long-term strategic planning and operational flexibility.

Sources

Save as PDF